Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2026-04-14 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Update - Notification regarding unquoted securities - PER 5 pages 16.6KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of unquoted securities by Percheron Therapeutics Limited. It includes specifics about the securities issued, dates, and references to a previous Appendix 3B announcement. The content focuses on the notification of securities issuance and updates to previous announcements, which aligns with announcements regarding share issues or capital changes. There is no financial report, earnings data, or management discussion present. Therefore, this document fits the category of Share Issue/Capital Change announcements.
2026-04-14 English
Results of Entitlement Offer 3 pages 143.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing the completion of a capital raising through a 2 for 5 Non-Renounceable Entitlement Offer, including specifics on shares and options issued, funds raised, and next steps for the company. It focuses on financing activities and capital structure changes, such as the issuance of new shares and options, and the use of proceeds. There is no indication that this is a full financial report, earnings release, or regulatory filing unrelated to capital. The document length is about 4912 characters, which is sufficient for a detailed announcement but not a full annual or interim report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2026-04-13 English
Non-renounceable Entitlement Offer Closing Date Reminder 2 pages 152.6KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement reminding shareholders about the closing date of a Non-Renounceable Entitlement Offer, which is a fundraising activity involving the issuance of new shares and options. It details the terms of the offer, record date, and instructions for shareholders to participate. There are no financial statements or detailed financial performance data included, and the document is relatively short (3476 characters). This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2026-04-01 English
New HMBD-002 Preclinical Data to be Presented at ASCO 2 pages 111.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about new preclinical data to be presented at an upcoming scientific conference (ASCO Annual Meeting). It does not contain any financial statements, management discussion, voting results, or regulatory filings. The content is primarily an announcement of upcoming data presentation rather than a report or detailed financial disclosure. The document length is short (2995 characters), and it is clearly an announcement rather than a full report or transcript. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2026-03-30 English
Non-renounceable Entitlement Offer Opens 1 page 257
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a non-renounceable entitlement offer, which is a type of rights issue allowing existing shareholders to purchase additional shares. It includes details about the prospectus availability, how shareholders can accept the offer, and the closing date for acceptance. There is no financial data, earnings information, or detailed report content. The document is focused on informing shareholders about a capital raising event and how to participate. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2026-03-23 English
Letter to Eligible Shareholders 3 pages 205.2KB
Capital/Financing Update Classification · 95% confidence The document is a notice to shareholders regarding a non-renounceable entitlement offer of new shares and options. It includes detailed information about the offer, eligibility, timetable, and instructions on how to participate. The content focuses on a capital raising event and the issuance of new shares and options, which is characteristic of a Capital/Financing Update. There is no indication that this is a full financial report, audit, or regulatory filing. The document is not a proxy statement, dividend notice, or management report. It is a formal announcement related to the company's capital structure changes.
2026-03-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.